Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bosentan.

Judy W M Cheng1

  • 1Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, and Mount Sinai Medical Center, New York, NY 10029, USA. jcheng@liu.edu

Heart Disease (Hagerstown, Md.)
|April 26, 2003
PubMed
Summary
This summary is machine-generated.

Bosentan, an endothelin receptor antagonist, improves symptoms in pulmonary arterial hypertension (PAH). Its potential extends to other vascular diseases, but requires careful monitoring due to side effects and drug interactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sodium-Glucose Cotransporter 2 Inhibitors Among Heart Failure With Mildly Reduced and Preserved Ejection Fraction.

The Annals of pharmacotherapy·2023
Same author

Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.

The Annals of pharmacotherapy·2020
Same author

Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.

Journal of cardiovascular pharmacology·2020
Same author

Reply: Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?

The Annals of pharmacotherapy·2019
Same author

Managing Diabetes and Preventing Heart Disease: Have We Found a Safe and Effective Agent?

The Annals of pharmacotherapy·2018
Same author

Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.

Current medical research and opinion·2017
Same journal

Ximelagatran: a new oral anticoagulant.

Heart disease (Hagerstown, Md.)·2003
Same journal

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

Heart disease (Hagerstown, Md.)·2003
Same journal

A comparison of humanistic qualities among medical students, residents, and faculty physicians in internal medicine.

Heart disease (Hagerstown, Md.)·2003
Same journal

Effect of carotid angioplasty-stenting on short-term mortality and stroke.

Heart disease (Hagerstown, Md.)·2003
Same journal

Evidence for the extrapulmonary localization of inhaled nitric oxide.

Heart disease (Hagerstown, Md.)·2003
Same journal

Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart.

Heart disease (Hagerstown, Md.)·2003
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Pulmonology

Background:

  • Pulmonary arterial hypertension (PAH) is a severe condition with limited treatment options.
  • Endothelin (ET) receptor antagonists represent a novel therapeutic class for PAH.
  • Bosentan is the first FDA-approved ET receptor antagonist for PAH management.

Purpose of the Study:

  • To review the efficacy and safety of bosentan in PAH patients.
  • To explore the potential of bosentan in other vascular diseases.
  • To highlight important considerations for bosentan therapy, including monitoring and drug interactions.

Main Methods:

  • Review of clinical trial data on bosentan in WHO Class III and IV PAH.
  • Discussion of ET's role in various vascular pathologies.

Related Experiment Videos

  • Analysis of bosentan's pharmacokinetic properties and known drug interactions.

    • Main Results:

    • Bosentan demonstrated significant improvements in dyspnea and exercise tolerance in PAH patients.
    • ET's involvement in heart failure, hypertension, ischemic heart disease, renal disease, and cerebrovascular disorders suggests potential for bosentan.
    • Bosentan is a substrate and inducer of CYP3A4 and CYP2C9, necessitating caution regarding drug interactions.

    Conclusions:

    • Bosentan is an effective treatment for PAH, improving key clinical endpoints.
    • Further research may elucidate bosentan's role in other vascular diseases.
    • Close patient monitoring for liver dysfunction and teratogenicity, alongside awareness of drug interactions, is crucial for safe bosentan use.